UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2018
Commission File Number:001-32001
Aptose Biosciences Inc.
(Translation of registrant’s name into English)
5955 Airport Road, Suite 228
Mississauga, Ontario L4V 1R9
Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☐ Form40-F ☑
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1) ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7) ☐
INCORPORATION BY REFERENCE
Exhibit 99.1 to this Report on Form6-K is hereby incorporated by reference as an Exhibit to the Registration Statement on FormF-10 of Aptose Biosciences Inc. (FileNo. 333-222909).
DOCUMENTS FILED AS PART OF THIS FORM6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Aptose Biosciences Inc. | ||||||
Date: March 28, 2018 | By: | /s/ Gregory Chow |
Name: | Gregory Chow | |||||||
Title: | Senior Vice President and Chief Financial Officer |
2
EXHIBIT INDEX
Exhibit | Description | |
99.1 | Sales Agreement, dated March 27, 2018 |